Nevro (NVRO) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to loss of $0.65 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 37.80%. A quarter ago, it was expected that this maker of an electrical implant that treats leg and back pain would post a loss of $0.63 per share when it actually produced a loss of $0.43, delivering a surprise of 31.75%.Over the l ...

公司财务状况 - 2024年第三季度全球营收9690万美元 较2023年第三季度下降6.7% 按固定汇率计算下降7.0% [3][4] - 2024年第三季度美国营收8390万美元 较上年同期下降约6.5% 永久植入手术量下降9.6% 试验手术量下降15.2% [3][5] - 2024年第三季度国际营收1300万美元 较2023年第三季度下降约7.7% 按固定汇率计算下降9.6% [3][6] - 2024年第三季度毛利润6460万美元 毛利润率66.7% 较2023年第三季度毛利润6950万美元和毛利润率66.9%有所下降 [6] - 2024年第三季度运营费用7850万美元 较上年同期9510万美元有所下降 排除特定项目后运营费用减少约1160万美元或12.2% [7] - 2024年第三季度诉讼相关法律费用为 - 60万美元 较2023年第三季度430万美元成本有大幅下降 [8] - 2024年第三季度运营净亏损1390万美元 排除特定项目后约为1890万美元 2023年第三季度运营净亏损2560万美元 [9] - 2024年第三季度调整后EBITDA亏损180万美元 较2023年第三季度亏损580万美元有所改善 [10] - 截至2024年9月30日 现金 现金等价物和短期投资总计2.77亿美元 较2024年6月30日增加330万美元 [11] 公司业务进展 - 2024年9月24日宣布美国FDA批准并限量推出HFX iQ AdaptivAI 预计2024年第四季度在美国全面上市 [3] - 2024年10月29日公布新数据 显示10kHz高频脊髓刺激疗法对疼痛性糖尿病神经病变和2型糖尿病患者有显著的疼痛缓解以及长期临床意义上的HbA1c和体重降低 [3] - 获得欧盟CE标志国家销售HFX iQ系统的监管批准 预计2024年第四季度在欧洲部分地区限量推出 2025年第一季度全面上市 [3] - Nevro1的比较生物力学数据被接受发表 在减少运动方面有优势且侵入性和破坏性更小 融合表面积最大 [3] 公司全年财务指引 - 基于2024年第三季度业绩和对今年剩余时间的展望 预计2024年全年全球营收约在4亿 - 4.05亿美元之间 [12] - 将2024年全年调整后EBITDA指引从之前的 - 2000万 - - 1800万美元提升至 - 1800万 - - 1600万美元 [12] 公司会议相关 - 将举办电话会议和网络直播讨论财务结果 可通过公司网站投资者关系板块观看直播和重播 也可通过电话接入会议 [14] 公司基本情况 - 是一家总部位于加利福尼亚州雷德伍德城的全球医疗器械公司 专注于提供慢性疼痛治疗解决方案 [16] - 拥有专有10 kHz疗法 影响全球超过11.5万名患者 [16] - 综合HFX脊髓刺激平台包括Senza SCS系统和支持服务 用于治疗躯干 肢体慢性疼痛和疼痛性糖尿病神经病变 [16] - 在美国为慢性骶髂关节疼痛患者增加了微创治疗选项 在骶髂关节融合领域提供最全面的产品组合 [17] - Senza Senza II Senza Omnia和HFX iQ是仅有的提供10 kHz疗法的SCS系统 有独特的支持服务 [18]

Analysis Marks the First Study of Spinal Cord Stimulation to Demonstrate Long-term, Significant, and Clinically Meaningful Reductions in HbA1c and Weight in Study Participants with Painful Diabetic Neuropathy and Type 2 Diabetes REDWOOD CITY, Calif., Oct. 29, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced the publication of new data in the Journal of Pain Research demo ...

REDWOOD CITY, Calif., Oct. 10, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it will release its financial results for the third quarter of 2024 after the market closes on Monday, November 11, 2024. The company will also host a conference call beginning at 1:30 p.m. PST (4:30 p.m. EST) to discuss its financial results. The live webcast and replay of the conference call w ...

Nevro (NVRO) is well-poised for growth in the coming quarters, courtesy of strength in Senza and diversification plans regarding product portfolio. The optimism, led by a decent second-quarter 2024 performance and continued focus on research and development activities, is expected to contribute further. However, concerns regarding softness in the spinal cord stimulation (SCS) market and dependence on thirdparty payers persist. This Zacks Rank #3 (Hold) company's shares have lost 74.9% in the year-to-date pe ...

Nevro (NVRO) recently announced the FDA clearance and limited market release of HFX iQ with HFX AdaptivAI, a responsive, personalized pain management platform powering the HFX iQ spinal cord stimulation (SCS) system. HFX AdaptivAI uses artificial intelligence (AI) to provide responsive, individualized pain treatment in real-time by combining insights from over 100,000 patients and over 100 million data points. Likely Trend of NVRO Stock Following the News Following the announcement, shares of the company cl ...

HFX AdaptivAI combines insights from over 100,000 patients and more than 100 million data points¹ and leverages artificial intelligence (AI) to deliver responsive and personalized pain relief in real time* REDWOOD CITY, Calif., Sept. 24, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced the U.S. Food and Drug Administration (FDA) approval and limited market release of HFX ...

REDWOOD CITY, Calif., Aug. 28, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that members of its management team will participate in a "fireside chat" (question-andanswer) session at the Wells Fargo 2024 Healthcare Conference on Friday, September 6, 2024, beginning at 8:45 a.m. EDT. A live webcast of the session and a replay of the webcast will be available on the Eve ...

Justin Paget Shares of Nevro Corp. (NYSE:NVRO) have fallen to fresh lows after the company reset the guidance for the year. This did not really come as a complete surprise to me after I concluded that the company was causing back pains for investors in February of last year. After multiple boom-bust cycles for the shares in the past, shares arrived at a bust phase again. Unlike previous episodes, I believe that the growth story has been impaired after revenues have been stagnant for a while. While the resul ...

Nevro Corp. (NVRO) reported a loss per share of 53 cents in the second quarter of 2024, narrower than the year-ago quarter's loss of 69 cents. The metric beat the Zacks Consensus Estimate of a loss per share of 63 cents. Revenues in Detail Nevro registered worldwide revenues of $104.2 million in the second quarter, down 4.3% year over year on a reported basis and 4.2% on a constant-currency basis. The year-over-year decline was primarily due to the result of competitive pressures in the U.S. spinal cord sti ...